Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the month of September 2020. The report serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a capital structure notification rather than a financial performance report.
| Metric | Value |
|---|---|
| Issued Share Capital (as of 31 August 2020) | 5,385,069,877 Ordinary Shares (25 pence each) |
| Treasury Shares | 367,705,950 |
| Total Voting Rights | 5,017,363,927 |
Material Changes
The filing text does not provide a clear value for material changes versus the prior comparable period regarding financial performance. The document solely establishes the share count and voting rights denominator as of 31 August 2020.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory disclosure of share capital and voting rights.
Investor Verification Checklist
- Verify the total number of voting rights (5,017,363,927) to determine notification thresholds under FCA rules.
- Confirm the number of shares held in Treasury (367,705,950) when calculating net outstanding shares.
- Note that this filing does not contain financial performance data; refer to Form 20-F or quarterly earnings releases for revenue and profit metrics.